Nkgen BiotechNKGN
13F holders, Q1 2025 (March 31)3holders −22
1new positions
23sold out
$0.18avg. 13F price*
At the end of Q1 2025, 3 institutions reported holding Nkgen Biotech Inc. (NKGN) in their 13F filings, down 22 from Q4 2024. 1 opened new positions and 23 sold out. The largest holders were Diametric Capital, LP ($93K), University of Chicago ($59K) and Flow Traders U.S. LLC ($9K).
- Company
- Nkgen Biotech Inc.
- CUSIP
- 65488A101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $9K |
| Exits | 23 | $4.4M |
All 13F filers, Q4 2024 → Q1 2025: 49,220 shares bought and 7,510,266 shares sold, net −7,461,046 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Diametric Capital, LP | 0.11% | No change | 518,134 | $93K |
| University of Chicago | 0.09% | Reduce -40.9% | 325,000 | $59K |
| Flow Traders U.S. LLC | 0.00% | New | 49,220 | $9K |
"% of holder's portfolio" is NKGN's weight in each manager's 13F, not the share of Nkgen Biotech Inc. the manager owns.